Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,473 across all filing types
Latest filing 2021-02-02 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 20201
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/1/2021 and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions during the month. The content is focused on share capital changes and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements to the exchange, not a financial report or announcement of a report. The document length is substantial (15,000 characters), indicating it is a full filing rather than a brief announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement about share capital movements that does not fit into more specific categories like Share Issue/Capital Change (SHA) because it is a monthly return report rather than a single event announcement.
2021-02-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 January 2021
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/01/2021, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content is focused on changes in the company's share capital structure during a specific month. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory filing reporting share capital movements, typical of a regulatory compliance report rather than a financial report or announcement of a report. It does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update, but aligns with Regulatory Filings (RNS) as a general compliance document reporting share capital movements to the exchange.
2021-02-01 English
CHANGE OF REGISTERED OFFICE, PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE IN THE CAYMAN ISLANDS
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change of the company's registered office and principal share registrar and transfer office in the Cayman Islands. It is a brief notice about administrative changes and does not contain financial data, management discussion, voting results, or any detailed report content. The document length is short (1332 characters), and it is clearly an announcement rather than a report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It also does not relate to board or management changes in personnel, only office address changes. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-02-01 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Ascletis Pharma Inc., detailing changes in issued share capital and share buybacks. It includes specific data on share issues, repurchases, and confirmations related to compliance with listing rules. The content focuses on reporting changes in share capital and share repurchases, which aligns with announcements regarding share capital changes rather than a full financial report or earnings release. The document is regulatory in nature, providing detailed disclosure about share capital changes and repurchases as required by the stock exchange rules. This fits the category of Share Issue/Capital Change (SHA) filings, which cover announcements about new share issues, stock splits, or other capital changes including share buybacks and cancellations. The document length (8491 characters) and detailed data support it being a full disclosure rather than a brief announcement or certification. Therefore, the appropriate classification is SHA with high confidence.
2021-01-14 English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES POSITIVE PHASE I CLINICAL RESULTS ON ITS THR-BETA AGONIST ASC41
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding positive Phase I clinical trial results for a drug candidate ASC41. It includes clinical trial data, safety profile, and pharmacokinetic information. There is no indication that this is a full financial report, audit report, or regulatory filing. The document is relatively short (3266 characters) and is an announcement of clinical trial results rather than a financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a shareholder meeting related document or capital/financing update. The content is scientific/clinical trial results announcement, which is typically classified under Regulatory Filings (RNS) as a general announcement that does not fit other financial or governance categories.
2021-01-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/12/2020 and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content is focused on share capital changes and confirmations related to securities issuance. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is a regulatory filing reporting monthly movements in securities and share capital, which fits the category of a Regulatory Filing (RNS) as it does not match other more specific categories like Share Issue/Capital Change (SHA) because it is a monthly return report rather than a single announcement of a capital change event. The document length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. Therefore, the best classification is Regulatory Filings (RNS).
2021-01-05 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.